Alogliptin: Difference between revisions

Alogliptin
	File:Alogliptin.svg
Clinical data
Routes of; administration	Oral
Identifiers
	IUPAC name 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-; 3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile;
CAS Number	850649-62-6;
PubChem CID	11450633;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C18H21N5O2
Molar mass	339.39 g/mol
3D model (JSmol)	Interactive image;
	SMILES N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC[C@@H](N)C2;

Revision as of 14:16, 4 September 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Alogliptin (codenamed SYR-322) is an investigational anti-diabetic drug in the DPP-4 inhibitor class,^[1] being developed by Takeda Pharmaceutical Company. Takeda has submitted a New Drug Application for alogliptin to the U.S. Food and Drug Administration, after positive results from Phase III clinical trials.^[2]

@@ Line 33: / Line 33: @@
 ==References==
-{{reflist}}
+{{reflist|2}}
 {{pharma-stub}}

Clinical data
File:Alogliptin.svg
Routes of administration	Oral
Identifiers
IUPAC name 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo- 3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile
CAS Number	850649-62-6
PubChem CID	11450633
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₈H₂₁N₅O₂
Molar mass	339.39 g/mol
3D model (JSmol)	Interactive image
SMILES N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC[C@@H](N)C2